Articles by tag: adc-therapy

FDA Fast Track for ADC ZW191 against resistant ovarian cancer

ADC ZW191 received Fast Track status from FDA for platinum-resistant ovarian cancer. ORR 64%, works with low FRα expression. Learn about the breakthrough and risks.

ADC drugs against resistant small cell lung cancer: breakthrough 2026

New class of ADC drugs targets DLL3 and B7-H3, overcoming SCLC resistance. Analysis of efficacy, toxicity, and treatment prospects. Read more.

ADC drug Decnupaz: treatment of ultra-rare blood cancer BPDCN

FDA approved pivekimab sunirin (Decnupaz) for BPDCN with complete remission of 69.7%. Analysis of efficacy, risks, price, and prospects in AML. Read more.